Ignyte Acquisition Corp.

Ignyte Acquisition Corp. (Nasdaq: PKBO) was a blank-check company that completed its initial public offering in 2022 and subsequently merged with Peak Bio, a clinical-stage biopharmaceutical company focused on oncology drug development. Sponsored by Ignyte Sponsor LLC, the vehicle targeted the life sciences sector. In November 2024, the company filed a Form 15-12G with the SEC, formally terminating its reporting obligations under Section 12(g) of the Exchange Act, indicating the post-combination entity no longer met the shareholder thresholds requiring continued registration. For full filing history, deal metrics, and ongoing SPAC coverage, sign up for a SpacDesk account at spacdesk.com.